Besides, STAT3 can be activated by other kinases explaining the survival of TKI-persistent CML cells treated with JAK-mediated STAT3 inhibitors [66]. This evidence concerns the gene STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive.